OGN — ORGANON & CO (Healthcare >> Drug Manufacturers - General)
OGN FAQ
What is OGN's P/E ratio?
ORGANON & CO (OGN) currently trades at a P/E ratio of 7.80.
What is OGN's ROE?
ORGANON & CO reports a Return on Equity (ROE) of 27.24%.
What is OGN's dividend yield?
ORGANON & CO offers a dividend yield of 0.60%.
What is OGN's Deepscope Quality Score?
Deepscope rates OGN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OGN?
Deepscope's AI Timing Score for OGN is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OGN belong to?
ORGANON & CO is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.
|
USD 13.36
Price
0.03
(0.22%)
Day Change
|
|
|---|
OGN, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
1471
|
| Magic Formula Rank by ROE |
1471
|
| Magic Formula Rank by ROIC |
668
|
| Price | 13.36 |
| PBV / Sector |
3.90 / 2.84
|
| Earning Per Share | 0.93 |
| PE / Sector |
7.80 / 24.53
GREAT
|
| PEG or PE/Growth / Sector |
-0.28 / 0.08
|
| Average 1M Daily Value |
39.50 M
GREAT
|
| Average 1W Daily Value |
28.55 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
41% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:57 |
| Symbol | OGN |
| Name | ORGANON & CO |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 262.60 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,518.85 / 241,254.65 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 30 Hudson Street, Jersey City, NJ, United States, 07302
Phone: 551 430 6900
Website: https://www.organon.com
Employees: 10,000
Description: Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google